Precedia answers one question for preclinical teams: what did FDA and EMA accept for programs like yours?
We read the public regulatory reviews for approved products across therapeutic modalities, from bispecific antibodies and antibody-drug conjugates to oligonucleotides, gene therapy and cell therapy, and lay out the nonclinical package behind each one:
ā¢ Which species carried the pivotal toxicology
ā¢ How long the longest studies ran
ā¢ Which studies were skipped, and the justification regulators accepted
ā¢ How the first-in-human dose was set
Every answer opens the regulators own sentence: the verbatim quote, the page number, and a link to the FDA or EMA source document. Every quote is verified word for word, and new modalities and products are added continuously.
Built for nonclinical leads, toxicologists, regulatory affairs teams and biotech founders planning IND/CTA-enabling programs, so you can see the precedent before you commit budget to studies.
Free to browse. No sign-up.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2026
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was Precedia founded?
Precedia was founded in 2026.
What industry is Precedia in?
Precedia operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Find investors for your startup like Precedia
Gritt sends AI-personalised outreach to each investor ā from your Gmail
